Research Topics
| JOSEPH O'DONOGHUESummaryAffiliation: Memorial Sloan-Kettering Cancer Center Country: USA Publications
| Collaborators
|
Detail Information
Publications
Hematologic toxicity in radioimmunotherapy: dose-response relationships for I-131 labeled antibody therapyJoseph A O'Donoghue
Memorial Sloan Kettering Cancer Center and Ludwig Institute for Cancer Research, New York, NY 10021, USA
Cancer Biother Radiopharm 17:435-43. 2002..Treatment may be prescribed on the basis of administered activity or absorbed dose. An optimal definition of maximum tolerated dose will enable the clinical benefits of RIT to be maximized...
Relevance of external beam dose-response relationships to kidney toxicity associated with radionuclide therapyJOSEPH O'DONOGHUE
Department of Medical Physics, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
Cancer Biother Radiopharm 19:378-87. 2004..Animal studies have also clarified the dose-dependency of the time to expression of radiation nephropathy and have indicated that radiation nephropathy may be alleviated by pharmacological means...
Assessment of regional tumor hypoxia using 18F-fluoromisonidazole and 64Cu(II)-diacetyl-bis(N4-methylthiosemicarbazone) positron emission tomography: Comparative study featuring microPET imaging, Po2 probe measurement, autoradiography, and fluorescent micJoseph A O'Donoghue
Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, NY, USA
Int J Radiat Oncol Biol Phys 61:1493-502. 2005..To compare two potential positron emission tomography (PET) tracers of tumor hypoxia in an animal model...
Noninvasive multimodality imaging of the tumor microenvironment: registered dynamic magnetic resonance imaging and positron emission tomography studies of a preclinical tumor model of tumor hypoxiaHyungJoon Cho
Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
Neoplasia 11:247-59, 2p following 259. 2009....
Evaluation of a compartmental model for estimating tumor hypoxia via FMISO dynamic PET imagingWenli Wang
Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
Phys Med Biol 54:3083-99. 2009....
In vivo characterization of a reporter gene system for imaging hypoxia-induced gene expressionSean Carlin
Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
Nucl Med Biol 36:821-31. 2009..To characterize a tumor model containing a hypoxia-inducible reporter gene and to demonstrate utility by comparison of reporter gene expression to the uptake and distribution of the hypoxia tracer (18)F-fluoromisonidazole ((18)F-FMISO)...
Image-guided PO2 probe measurements correlated with parametric images derived from 18F-fluoromisonidazole small-animal PET data in ratsRachel M Bartlett
Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
J Nucl Med 53:1608-15. 2012..The objective of this study was to determine whether kinetic analysis of dynamic (18)F-fluoromisonidazole data provides better discrimination of tumor hypoxia than methods based on a simple tissue-to-plasma ratio...
Radiosynthesis of [(131)I]IAZGP via nucleophilic substitution and its biological evaluation as a hypoxia marker - is specific activity a factor influencing hypoxia-mapping ability of a hypoxia marker?Makiko Suehiro
Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
Nucl Med Biol 36:477-87. 2009....
Image deconvolution in digital autoradiography: a preliminary studyMutian Zhang
Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
Med Phys 35:522-30. 2008..Digital autoradiograms following deconvolution show improved sharpness and contrast relative to the unprocessed autoradiograms...
Phase I study of samarium-153 lexidronam with docetaxel in castration-resistant metastatic prostate cancerMichael J Morris
Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
J Clin Oncol 27:2436-42. 2009..To build on this strategy and fully integrate a repetitively dosed bone-seeking radiopharmaceutical into a contemporary chemotherapy regimen, we conducted a phase I study of docetaxel and samarium-153 ((153)Sm) lexidronam...
Preclinical radioimmunotargeting of folate receptor alpha using the monoclonal antibody conjugate DOTA-MORAb-003Peter M Smith-Jones
Nuclear Medicine Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, Box 77, New York, NY 10021, USA
Nucl Med Biol 35:343-51. 2008..The in vitro and in vivo behavior of the radiolabeled monoclonal antibody MORAb-003 was investigated as a prelude to a clinical trial...
